Last edition
News about "Kazia Therapeutics and QIMR Berghofer Partner"
Kazia Therapeutics Limited, a Sydney-based oncology-focused drug development company, has entered into an exclusive collaboration and in-licensing agreement with QIMR Berghofer to advance a pioneering PD-L1 degrader programme.
Kazia Therapeutics And QIMR Berghofer Partner | 11/10/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members